Intel stock spikes after report of possible US government stake
Investing.com -- Straumann Holding AG (SIX:STMN) shares fell more than 4% on Wednesday after the Swiss dental implant maker reported second-quarter and first-half results that missed consensus estimates for sales, EBIT and earnings per share, despite organic growth slightly topping forecasts.
First-half 2025 sales totaled 1.35 billion Swiss francs ($1.54 billion), 1% below consensus, while organic growth reached 10.2%, slightly above expectations.
Core EBIT was 358 million francs, 2% under consensus, for a margin of 26.6%. Earnings per share missed by 8%, with the company citing higher interest costs tied to foreign exchange losses.
North America posted 2.7% organic growth in the second quarter, above the 2.2% consensus, with stable patient flow in the United States, Barclays (LON:BARC) said.
Europe, the Middle East and Africa delivered 9.1% organic growth in the first half, aided by affordability, a multi-brand strategy and favorable geographic and product mix, according to Jefferies.
Asia Pacific sales were 1% below consensus, though organic growth was 19.6%. China is expected to remain a major growth driver, with 2025 organic growth of 10% to 15% seen as reasonable, Jefferies said.
Latin America outperformed with 16.2% growth in the quarter, driven by the Neodent brand, Barclays said.
Straumann confirmed its 2025 guidance for high-single-digit organic revenue growth and a 30- to 60-basis-point improvement in core EBIT margin at constant 2024 currency rates.